Table 1 Demographics of Delphi participants

From: A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials

 

Round 1 (N = 470)

Round 2 (N = 336)

Rolea

  

Surgeona

Medical Oncologist

Radiation Oncologistc

Otherd

206 (43.8)

144 (30.6)

98 (20.8)

22 (4.7)

153 (45.5)

90 (26.8)

77 (22.9)

16 (4.8)

Age

  

<30

30-39

40-49

50-59

60 or over

Prefer not to say/not reported

5 (1.1)

96 (20.4)

158 (33.6)

146 (31.1)

56 (11.9)

9 (1.9)

4 (1.2)

69 (20.5)

118 (35.1)

99 (29.5)

39 (11.6)

7 (2.1)

Geographical location of practice

  

Europe

Asia

North America

South America

Australia/New Zealand

Middle East

Africa

274 (58.3)

60 (12.8)

46 (9.8)

38 (8.1)

32 (6.8)

14 (3.0)

6 (1.3)

209 (62.2)

45 (13.4)

30 (8.9)

19 (5.7)

20 (6.0)

9 (2.7)

4 (1.2)

Gender

  

Female

Male

Prefer not to say/not reported

248 (55.8)

213 (45.2)

9 (1.9)

173 (51.5)

155 (46.1)

8 (2.4)

Years of experience at Consultant/Attending level

  

 < 5 years

5–10 years

>10 years

Prefer not to say/ not reported

64 (13.6)

94 (20.0)

307 (65.3)

5 (1.1)

47 (14.0)

69 (20.5)

216 (64.3)

4 (1.2)

Main type of practice

  

Academic/University/Teaching Hospital

Public Hospital

Private Hospital

Other

338 (71.9)

58 (12.3)

56 (11.9)

18 (3.8)

246 (73.2)

38 (11.3)

40 (11.9)

12 (3.6)

Research activee

437 (93.0)

316 (94.1)

  1. aIf more than one role stated, respondents were classified according to involvement in locoregional breast cancer treatments.
  2. b13 surgeons also prescribed chemotherapy.
  3. cIncludes 1 Consultant Therapeutic Radiographer (RTT) and 18 respondents who prescribed chemotherapy and gave radiation therapy.
  4. dRadiologist n = 4; pathologist n = 2; non-clinical role n = 6, not stated = 3.
  5. eDefined broadly as designing, leading or recruiting to clinical trials or other research studies.